Summit Therapeutics Inc. (NASDAQ:SMMT) said partner Akeso reported a statistically significant overall survival benefit for ivonescimab monotherapy over pembrolizumab in a prespecified interim analysis of Phase 3 HARMONi-2. The randomized, double-blind study enrolled 398 patients at 55 hospitals in China with previously untreated, PD-L1-positive advanced non-small cell lung cancer without sensitizing EGFR mutations or ALK translocations.
Overall survival was a prespecified secondary endpoint. Earlier analysis showed median progression-free survival of 11.1 months with ivonescimab and 5.8 months with pembrolizumab. The hazard ratio was 0.51, representing a 49% reduction in the risk of progression or death.
However, Summit Therapeutics Inc. did not disclose the overall-survival hazard ratio, confidence interval, median survival, data maturity, or follow-up duration. Akeso reported that the interim analysis met the key secondary endpoint, but its commercial and regulatory importance depends on the benefit’s magnitude and consistency.
Bull Case
Overall survival tests whether patients live longer, strengthening the result beyond the previously demonstrated delay in disease progression. Pembrolizumab is an established first-line treatment in PD-L1-positive disease, so a head-to-head survival advantage provides stronger evidence than comparison with placebo or chemotherapy alone.
Ivonescimab combines PD-1 blockade with VEGF inhibition in one bispecific antibody. The molecule is designed to counter immune suppression and angiogenesis, with cooperative binding intended to increase activity where PD-1 and VEGF coexist in the tumor microenvironment. HARMONi-2 previously showed progression-free survival benefits across low and high PD-L1 expression and squamous and non-squamous histologies. In the PD-L1-high subgroup, the progression-free-survival hazard ratio was 0.48.
That subgroup is relevant to HARMONi-7, the randomized, double-blind, multiregional Phase 3 trial sponsored by Summit Therapeutics Inc.. HARMONi-7 compares the same two monotherapies as first-line treatment for metastatic disease with PD-L1 expression of at least 50%. A successful global study could provide the direct bridge that HARMONi-2 cannot establish alone.
Bear Case
The missing effect size prevents a full assessment. An April 2025 analysis at 39% data maturity produced an overall-survival hazard ratio of 0.777, indicating a numerical 22% reduction in the risk of death but not statistical significance at that analysis. The new result may reflect a stronger treatment effect, additional events, or both. Summit Therapeutics Inc. has not yet provided enough data to distinguish among those possibilities.
Safety also matters for a therapy that adds VEGF inhibition to checkpoint blockade. In the published progression-free-survival analysis, grade 3 or higher treatment-related adverse events occurred in 29% of ivonescimab patients and 16% of pembrolizumab patients. Grade 3 or higher immune-related events were similar at 7% and 8%, respectively, but updated safety and discontinuation data were not disclosed with the survival announcement.
HARMONi-2 was sponsored, managed, and analyzed by Akeso in one country. Differences in patient characteristics, subsequent treatments and clinical practice may affect transferability. Ivonescimab is approved in China but remains investigational and unapproved in the licensed territories of Summit Therapeutics Inc., including the United States and Europe.
Hedge Fund Sentiment
The filings available so far reflect positions held before Summit Therapeutics Inc. reported the HARMONi-2 overall-survival result. Insider Monkey’s database showed 39 hedge funds holding Summit Therapeutics Inc. at the end of 2Q2026, up from 34 funds three months earlier.
Conclusion
The HARMONi-2 survival result materially strengthens the clinical case for ivonescimab after the earlier progression-free-survival advantage. It does not establish the benefit’s magnitude or durability, or whether it will reproduce outside China. For Summit Therapeutics Inc., full survival, subgroup, and safety data will clarify the result, while HARMONi-7 will test global transferability in first-line PD-L1-high metastatic NSCLC.
READ NEXT: Main Street Capital’s (MAIN) Blowout Exit Fuels A Bigger Dividend and Here is Why Chevron (CVX) is a Favorite Among Hedge Funds
This article is originally published at Insider Monkey.
